Pre and post-renal transplantation high soluble CD30 (sCD30), a marker for T helper 2-type cytokine-producing T cells, is a relevant predictor for development of rejection episodes and may contribute further to the selection of appropriate immunosuppressive regimens in high risk recipients. In this study we intended to evaluate the accuracy of serial sCD30 post-transplantation as a predictor for acute rejection versus other markers which affect graft outcome over one year. Fifty renal transplant recipients were randomly selected to check sCD 30 at day 0, 3, 5, 7, 14, 21, 1 month, 3 months, 6 months and 12 months post-transplantation. Results were analyzed for development of acute rejection, (Acute Tubular Necrosis) ATN or other pathology and graft outcome at one year. Compared with pre-transplantation sCD30, there was significant reduction of the average sCD30 immediately post-transplantation from day 3 onwards (p <0.0001). One graft was lost due to renal vein thrombosis immediately post transplantation. Patients were divided into four groups: 1- Uncomplicated course (56%), 2- Acute rejection (18%), 3- ATN (16%) and 4- Other diagnoses (10%). There was significant reduction of sCD30 immediately post-transplantation for group 1, 2 and 3(p <0.0001, 0.004 and 0.002 respectively) but not group 4 (p 0.387). Patients who developed acute rejection after one month had higher pre-transplantation sCD30 value than others who had rejection before one month (p 0.019) with odds ratio 1.649 for the graft loss. All groups had significant improvement of graft function over one year of follow up without significant difference between them. Conclusion: Though significant drop of sCD30 post-transplanation is recorded, measuring sCD30 serially post-transplantation didn’t help to differentiate between acute rejection, ATN and other diagnoses. In this study, higher sCD30 levels pre-transplantation were reported in patients who developed rejection episodes later than one month of transplantation.